Abstract
In the 3 years since residual gadolinium-based contrast agent (GBCA) in the brain was first reported, much has been learned about its accumulation, including the pathway of GBCA entry into the brain, the brain distribution of GBCA and its excretion. Here we review recent progress in understanding the routes of gadolinium deposition in brain structures.
MeSH terms
-
Animals
-
Brain / diagnostic imaging
-
Brain / metabolism*
-
Cerebellar Nuclei / diagnostic imaging
-
Cerebellar Nuclei / metabolism
-
Contrast Media / administration & dosage
-
Contrast Media / adverse effects
-
Contrast Media / chemistry
-
Contrast Media / pharmacokinetics*
-
Environmental Pollutants / pharmacokinetics
-
Gadolinium / administration & dosage
-
Gadolinium / adverse effects
-
Gadolinium / chemistry
-
Gadolinium / pharmacokinetics*
-
Gadolinium DTPA / administration & dosage
-
Gadolinium DTPA / pharmacokinetics
-
Globus Pallidus / diagnostic imaging
-
Globus Pallidus / metabolism
-
Heterocyclic Compounds / administration & dosage
-
Heterocyclic Compounds / pharmacokinetics
-
Humans
-
Magnetic Resonance Imaging
-
Meglumine / administration & dosage
-
Meglumine / pharmacokinetics
-
Organometallic Compounds / administration & dosage
-
Organometallic Compounds / pharmacokinetics
-
Rats
Substances
-
Contrast Media
-
Environmental Pollutants
-
Heterocyclic Compounds
-
Organometallic Compounds
-
gadoteridol
-
gadobutrol
-
Meglumine
-
Gadolinium
-
Gadolinium DTPA
-
gadoterate meglumine